Robert J. Dempsey to lead TearClear as CEO
Click Here to Manage Email Alerts
The ophthalmic pharmaceutical company TearClear has named Robert J. Dempsey as CEO.
“We are emerging as a global leader in treating glaucoma and inflammatory conditions such as dry eye disease,” Dempsey said in a company press release. “TearClear is producing medications that address a critical unmet need for preservative-free eye drops, and I’m excited to lead this effort with the team.”
Dempsey has more than 20 years of ophthalmic pharmaceutical industry experience, previously serving as the global head of ophthalmology at Shire, and he was responsible for one of the largest biopharma mergers of 2019, the release said.
“With his background and experience in successfully leading commercialization strategies in the pharmaceutical industry, Bob can guide TearClear to becoming a leader in the ophthalmology industry,” board chairman William Link, PhD, said in the release.
As he takes the reins amidst the uncertainties of the COVID-19 pandemic, Dempsey told Healio/OSN: “The number one concern of the business is to maintain the safety of the employees. We are in constant communications with them and keeping them informed. In addition, all of our suppliers have been informed that their employees are ‘essential employees.’ We are in contact with the leaders of these organizations. Lastly, we are still planning on executing our clinical development programs and have not experienced any delays yet.” –by Erin T. Welsh
Editor’s note: This article has been updated to include comment from Robert J. Dempsey.